ERYTECH Pharma (NASDAQ: ERYP) is perhaps the best performing stock in the world today, rising more than 90% in a dramatic day of trading.
If you want to invest in ERYTECH Pharma because it is one of today’s biggest gainers in the stock market, this article will help inform your investment. Read one to discover what the company is, why it is surging in value and what our Erytech price target is for 2021.
For those of you who want to buy ERYP shares quickly and easily, simply click on one of the links in the section below to sign up to one of the best places to buy Erytech Pharma stock.
How & where to buy Erytech stock online
To invest in ERYP stock, simply click on one of the links below, fill out some information, sign up, and fund your new account. Then, you can search for ERYP stock, choose the number of shares you want to buy, and execute your transaction.
Here are the two best platforms to buy Erytech Pharma shares today:
eToro is one of the world's leading multi-asset trading platforms offering some of the lowest commission and fee rates in the industry. It's social copy trading features make it a great choice for those getting started.
Financial company driven by technology and offering all-in-one self-directed investment platform that provides excellent user experience.
What is Erytech Pharma?
Incorporated in 2004 and headquartered in Lyon, France, it is a clinical-stage biopharmaceutical company that is developing red blood cell-based therapeutics for cancer and organ diseases in France and the United States.
The company’s lead product is Eryaspase, which is currently in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in the Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients.
The stock has skyrocketed in price on heavy volume following positive news: the France-based biopharmaceutical company has declared that its treatment for hypersensitive acute lymphocytic leukemia (ALL) patients was granted Fast Track designation by the Food and Drug Administration. This could accelerate commercialisation drastically.
Should I buy Erytech Pharma stock today?
Investing in biopharmaceutical companies is always risky, but if you feel this latest news is the breakthrough moment for Erytech, and if you feel its treatments can achieve commercial success, investing now could be a good way to seek exposure to future growth.
Erytech Pharma price target 2021
Based on our analysis, our 12-month ERYP price target is as follows: a median of $20, with a high estimate of $22.40 and a low estimate of $13.